Literature DB >> 23323935

Interleukin-33 and alveolar macrophages contribute to the mechanisms underlying the exacerbation of IgE-mediated airway inflammation and remodelling in mice.

Nobuaki Mizutani1, Takeshi Nabe, Shin Yoshino.   

Abstract

Allergen-specific IgE has long been regarded as a major molecular component of allergic asthma. Additionally, there is increasing evidence of the important roles of interleukin-33 (IL-33) in the disease. Here, we show that IL-33 and alveolar macrophages play essential roles in the exacerbation of IgE-mediated airway inflammation and remodelling. BALB/c mice passively sensitized with ovalbumin (OVA)-specific IgE monoclonal antibody (mAb) were challenged with OVA seven times intratracheally. The seventh challenge exacerbated airway inflammation and remodelling compared with the fourth challenge; furthermore, markedly increased expression of IL-33 in the lungs was observed at the fourth and seventh challenges. When anti-IL-33 or anti-ST2 antibody was administered during the fourth to seventh challenge, airway inflammation and remodelling were significantly inhibited at the seventh challenge. Because increases of IL-33(+) and ST2(+) alveolar macrophages and ST2(+)  CD4(+) T cells in the lungs were observed at the fourth challenge, the roles of macrophages and CD4(+) cells were investigated. Depletion of macrophages by 2-chloroadenosine during the fourth to seventh challenge suppressed airway inflammation and remodelling, and IL-33 production in the lung at the seventh challenge; additionally, anti-CD4 mAb inhibited airway inflammation, but not airway remodelling and IL-33 production. Meanwhile, treatment with 2-chloroadenosine or anti-CD4 mAb decreased IL-33-induced airway inflammation in normal mice; airway remodelling was repressed only by 2-chloroadenosine. These results illustrate that macrophage-derived IL-33 contributes to the exacerbation of IgE-mediated airway inflammation by mechanisms associated with macrophages and CD4(+) cells, and airway remodelling through the activation of macrophages.
© 2013 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23323935      PMCID: PMC3647187          DOI: 10.1111/imm.12071

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  53 in total

Review 1.  Alternative activation of macrophages.

Authors:  Siamon Gordon
Journal:  Nat Rev Immunol       Date:  2003-01       Impact factor: 53.106

2.  Inhibition of airway remodeling in IL-5-deficient mice.

Authors:  Jae Youn Cho; Marina Miller; Kwang Je Baek; Ji Won Han; Jyothi Nayar; Sook Young Lee; Kirsti McElwain; Shauna McElwain; Stephanie Friedman; David H Broide
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

Review 3.  The significance of late responses in asthma.

Authors:  S R Durham
Journal:  Clin Exp Allergy       Date:  1991-01       Impact factor: 5.018

4.  Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study.

Authors:  P K Jeffery; R W Godfrey; E Adelroth; F Nelson; A Rogers; S A Johansson
Journal:  Am Rev Respir Dis       Date:  1992-04

5.  Regulation of immune response to inhaled antigen by alveolar macrophages: differential effects of in vivo alveolar macrophage elimination on the induction of tolerance vs. immunity.

Authors:  T Thepen; C McMenamin; J Oliver; G Kraal; P G Holt
Journal:  Eur J Immunol       Date:  1991-11       Impact factor: 5.532

6.  ST2 protein induced by inflammatory stimuli can modulate acute lung inflammation.

Authors:  Katsuhisa Oshikawa; Ken Yanagisawa; Shin ichi Tominaga; Yukihiko Sugiyama
Journal:  Biochem Biophys Res Commun       Date:  2002-11-22       Impact factor: 3.575

Review 7.  T1/ST2--an IL-1 receptor-like modulator of immune responses.

Authors:  Vladimir Trajkovic; Matthew J Sweet; Damo Xu
Journal:  Cytokine Growth Factor Rev       Date:  2004 Apr-Jun       Impact factor: 7.638

8.  Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation.

Authors:  Zhou Zhu; Tao Zheng; Robert J Homer; Yoon-Keun Kim; Ning Yuan Chen; Lauren Cohn; Qutayba Hamid; Jack A Elias
Journal:  Science       Date:  2004-06-11       Impact factor: 47.728

9.  Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma.

Authors:  D S Robinson; Q Hamid; S Ying; A Tsicopoulos; J Barkans; A M Bentley; C Corrigan; S R Durham; A B Kay
Journal:  N Engl J Med       Date:  1992-01-30       Impact factor: 91.245

Review 10.  Asthma: mechanisms of disease persistence and progression.

Authors:  Lauren Cohn; Jack A Elias; Geoffrey L Chupp
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

View more
  18 in total

1.  Anti-IL-33 Antibody Has a Therapeutic Effect in an Atopic Dermatitis Murine Model Induced by 2, 4-Dinitrochlorobenzene.

Authors:  Ge Peng; Zhenzhen Mu; Lixia Cui; Pengyue Liu; Ying Wang; Wenqing Wu; Xiuping Han
Journal:  Inflammation       Date:  2018-02       Impact factor: 4.092

2.  Antigen-specific airway IL-33 production depends on FcγR-mediated incorporation of the antigen by alveolar macrophages in sensitized mice.

Authors:  Takeshi Nabe; Masaya Matsuda; Tomoki Ishida; Nau Tsujimoto; Hitomi Kido; Haruna Kanaya; Hiromu Takahashi; Naoki Takemoto; Miku Nomura; Keiichi Ishihara; Satoshi Akiba; Nobuaki Mizutani
Journal:  Immunology       Date:  2018-04-19       Impact factor: 7.397

Review 3.  The Potential for Emerging Microbiome-Mediated Therapeutics in Asthma.

Authors:  Ayse Bilge Ozturk; Benjamin Arthur Turturice; David L Perkins; Patricia W Finn
Journal:  Curr Allergy Asthma Rep       Date:  2017-08-10       Impact factor: 4.806

4.  Type 2 innate lymphoid cells participate in IL-33-stimulated Th2-associated immune response in chronic obstructive pulmonary disease.

Authors:  Min Jiang; Simin Tao; Shaohua Zhang; Jing Wang; Fengbo Zhang; Fengsen Li; Jianbing Ding
Journal:  Exp Ther Med       Date:  2019-08-20       Impact factor: 2.447

5.  Virus-like particles presenting interleukin-33 molecules: immunization characteristics and potentials of blockingIL-33/ST2 pathway in allergic airway inflammation.

Authors:  Qiong Long; Weiwei Huang; Yufeng Yao; Xu Yang; Wenjia Sun; Xiaomei Jin; Yang Li; Xiaojie Chu; Cunbao Liu; Zhikang Peng; Yanbing Ma
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  IgE/antigen-mediated enhancement of IgE production is a mechanism underlying the exacerbation of airway inflammation and remodelling in mice.

Authors:  Nobuaki Mizutani; Takeshi Nabe; Shin Yoshino
Journal:  Immunology       Date:  2015-01       Impact factor: 7.397

7.  Ambient particulate matter induces an exacerbation of airway inflammation in experimental asthma: role of interleukin-33.

Authors:  A M Shadie; C Herbert; R K Kumar
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

Review 8.  Pulmonary Macrophage Cell Death in Lung Health and Disease.

Authors:  Abigail M Shotland; Andrew P Fontenot; Amy S McKee
Journal:  Am J Respir Cell Mol Biol       Date:  2021-05       Impact factor: 6.914

9.  Vaccination against IL-33 Inhibits Airway Hyperresponsiveness and Inflammation in a House Dust Mite Model of Asthma.

Authors:  Ying Lei; Vamsi Boinapally; Anna Zoltowska; Mikael Adner; Lars Hellman; Gunnar Nilsson
Journal:  PLoS One       Date:  2015-07-27       Impact factor: 3.240

10.  Interleukin-33 drives activation of alveolar macrophages and airway inflammation in a mouse model of acute exacerbation of chronic asthma.

Authors:  Melissa M Bunting; Alexander M Shadie; Rylie P Flesher; Valentina Nikiforova; Linda Garthwaite; Nicodemus Tedla; Cristan Herbert; Rakesh K Kumar
Journal:  Biomed Res Int       Date:  2013-07-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.